The invention pertains to utilization of pterostilbene for augmenting immunogenicity of cancer cells treated with various therapies.
OCEANSIDE, CA–(iHub – October 16, 2017) – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced the filing of an additional patent on the use of pterostilbene.
TSOI had previously announced the granting of U.S. Patent No.: 9,682,047 for our flagship product ProJuvenol as an immuno-adjuvant to FDA approved chemotherapies and immunotherapies. In addition we have also filed an application with the U.S. Patent and Trademark Office for the means of augmenting circulating endogenous stem cells through administration of an effective amount of pterostilbene or derivatives thereof.
“Today’s announcement of the filing of our third pterostilbene patent represents several years of research and literature review and was developed to utilize the ability of the immune system to augment the possibility of increasing overall survival of glioma patients after treatment with conventional therapies. Our data suggests that when pterostilbene is combined with brain cancer therapeutics such as Gefitinib, Sertraline, or Temozolomide, the prognosis is vastly improved”, said co-inventor Timothy Dixon, President and CEO.
“What is particularly interesting is that pterostilbene appears to make cancer cells more visible to the immune system subsequent to their being attacked by conventional drug approaches”, said Dr. Thomas Ichim, Board Member of TSOI and co-inventor of patent. “Specifically, we observed that this increase of immunogenicity that pterostilbene causes in chemotherapy treated cancer cells allows for enhanced immunity to cancer cells that have escaped chemotherapy, thus theoretically enhancing patient prognosis.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is www.therapeuticsolutionsint.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
- Therapeutic Solutions International, Inc.